Introduction
============

With the advent of new immunological therapies for the treatment of multiple sclerosis (MS), the complexity of managing disease-modifying therapies (DMTs) has increased. The first-line injectable DMTs, including interferon β and glatiramer acetate, have been available for almost 20 years; they have known adverse events and benefits.[@b1-ppa-8-971] Newer therapies have different risk--benefit profiles compared to the first-line therapies, but all are used to prevent relapses, increase in lesion burden, and progression of disability.[@b1-ppa-8-971] Physicians managing DMTs must consider many factors, including how to tailor therapy to the needs of the individual patient.[@b2-ppa-8-971]

The evaluation of which drug is appropriate for which patient is challenging for the physician and patient, especially in the event of relapses or progression while on a DMT. Switching among DMTs in the case of breakthrough disease appears to be common practice.[@b2-ppa-8-971] Adverse events, adherence, cost, and risk tolerances are all important considerations in the decision to switch medications;[@b3-ppa-8-971] even at similar disability levels, the importance of these factors on decision-making varies between patients.[@b2-ppa-8-971]

Increasingly, clinicians and researchers recognize the importance of and need for shared decision-making in complex treatment decisions.[@b4-ppa-8-971],[@b5-ppa-8-971] Therefore, understanding of the patient perspective regarding their rationale and motivation for switching DMTs is important, as is assessing differences in sociodemographic factors and disease characteristics among the participants switching to different DMTs. Our exploratory hypothesis was that there would be clinical and sociodemographic differences between those participants who initiated a switch compared to the physician-initiated switchers, and that the differences may depend on the DMT group to which the participant switched.

Methods
=======

North American Research Committee on Multiple Sclerosis (NARCOMS) registry
--------------------------------------------------------------------------

The NARCOMS registry is a voluntary, self-report registry of persons with MS. The diagnosis of MS has been validated in a random sample of registry participants.[@b6-ppa-8-971] Participants complete an enrollment survey and update their clinical and sociodemographic information through semi-annual surveys. Although the NARCOMS registry is not population-based, the characteristics of the registry population are similar to those reported for other MS populations,[@b7-ppa-8-971],[@b8-ppa-8-971] and other MS volunteer samples have been found to be representative of the wider population of persons with MS.[@b9-ppa-8-971]

Patient's Perspective survey
----------------------------

NARCOMS mailed a "Patient's Perspective" supplemental survey to those registry participants who had reported switching a DMT in the 2011 spring or fall surveys. Inclusion criteria for the analyses were based on NARCOMS update survey information and the returned supplemental survey, and were 1) a relapsing disease course, and 2) affirmative response to a single question about whether their DMT had changed in the past 6 months, after September 2010. Participants identified their current DMT and the length of use, frequency of administration, and perceived efficacy of that DMT. Also, participants reported which DMT they had taken immediately prior to their current DMT, and how long they were on that DMT. The primary reasons for making the decision to switch were recorded ([Figure 1A](#f1-ppa-8-971){ref-type="fig"}). In addition to the primary reasons for switching, secondary reasons were also of interest. To identify secondary reasons for the switching decision, we provided the same response options as for the primary reasons but allowed respondents the option to select as many as were applicable. The participants who initiated the discussion to switch were asked their reasons for the initiation of the discussion with their physician ([Figure 1B](#f1-ppa-8-971){ref-type="fig"}). The response options for both sets of questions were related to efficacy, safety, side effects, and medical tolerance.

Analysis
--------

Sociodemographic and clinical information of all study participants were gathered from the standard survey information already collected in the NARCOMS registry. Race was included as a dichotomous variable: Caucasian (reference group), and non-Caucasian. Education was analyzed as a categorical variable: high school diploma or less (reference group); associate's degree or technical degree; bachelor's degree; or postgraduate degree, as was annual household income (USD): \<\$15,000 (reference group); \$15,000--\$29,999; \$30,000--\$49,999; \$50,000--\$100,000; \>\$100,000; or declined to answer. Insurance status was categorized as private, public only (reference group), or none.

The Patient-Determined Disease Steps (PDDS) score, relapse history, and symptom worsening are routinely collected in NARCOMS surveys. The PDDS is a validated 9-point self-report measure, which correlates highly with the expanded disability status scale (EDSS).[@b10-ppa-8-971]--[@b12-ppa-8-971] It is an ordinal scale ranging from 0 (normal, reference group) to 8 (bedbound). Participants report relapses that occurred in the prior 6 months and whether their MS symptoms worsened in a gradual, progressive manner over the past 6 months. These variables were used, when available, for the years preceding the switch. Providers managing care included MS specialist, neurologist (reference group), general neurologist, primary health care provider, and other. Data from the fall 2011 update survey were used to verify the specific DMT changes reported by the participant in the Patient's Perspective survey, which was administered approximately 3 months later.

The DMTs were categorized as first-line injectables (interferon β-1a, interferon β-1b, glatiramer acetate); oral therapies (fingolimod); infusion therapies (natalizumab, rituximab, alemtuzumab, daclizumab), although no participant switched to rituximab, alemtuzumab, or daclizumab; or other (eg, IVIG \[intravenous immunoglobulin\] and combinations of DMTs). Data on current and past DMT use reported on the supplemental surveys were utilized to verify eligibility for study inclusion and the past semi-annual survey data were used for confirmation. Type and duration of current and past DMT use were covariates in the analyses.

We summarized categorical variables using frequency (percent) and continuous variables using mean (standard deviation) or median (interquartile range \[IQR\]) as appropriate. Missing responses were not imputed. Univariate comparisons among DMT groups and among the physician-initiated and participant-initiated switchers used chi-square tests and Fisher's exact tests for categorical variables (sex, race, doctor managing the participant's MS, and past and switched-to DMT); Wilcoxon test for median PDDS score; and analysis of variance for continuous variables (age and disease duration). Logistic regression was used to compare differences in clinical and sociodemographic factors between those participants who would consider switching again and those who would not. Dependent variables were selected from those in [Table 1](#t1-ppa-8-971){ref-type="table"} and the variable was kept in the model if *P*\<0.05. An alpha level \<0.001 was used for these analyses in order to limit the number of false positive tests due to the multiple tests being conducted. Analyses were performed using SAS software (v9.2; SAS Institute Inc., Cary, NC, USA).

Standard protocol approvals, registrations, and patient consent
---------------------------------------------------------------

NARCOMS participants agree to the use of their de-identified data for research purposes. The semi-annual surveys and the supplemental survey were approved by the University of Alabama at Birmingham (Birmingham, AL, USA) institutional review board.

Results
=======

There were 10,591 unique registry participants who responded to at least one of the two routine surveys in 2011 and, of these participants, 40.5% reported not taking any DMT. Six hundred and ninety-one (6.5% of the total or 10.9% of those taking a DMT) reported switching DMTs and were sent the supplemental survey ([Figure 2](#f2-ppa-8-971){ref-type="fig"}). From those 691 potential candidates, 470 (68.6%) responded. Thirty-four percent (n=162) of responders did not fully meet the inclusion criteria: ten were participating in a clinical trial for a DMT not currently approved by the US Food and Drug Administration (FDA); 73 switched before September 2010; 67 did not actually change medication (ie, had dose or frequency changes or stopped medication); and 12 described themselves as experiencing a primary progressive disease course. Responders (n=470) were more likely to be Caucasian (*P*=0.007), older (*P*=0.0009), and to have a slightly longer disease duration (*P*=0.005) than nonresponders. However, when comparing the analysis participants (n=308) to the nonresponders, no differences in disease duration (*P*=0.11) or age (*P*=0.08) were seen, and the nonresponders were less likely to be Caucasian (*P*=0.006).

The study participants included in the analyses (n=308) were primarily female (83.4%), and over one-half were at or above a disability level requiring the use of a cane (PDDS score ≥4) ([Table 1](#t1-ppa-8-971){ref-type="table"}). This subset was representative of the active registry participants and of persons with MS who have had the disease for more than 10 years.[@b7-ppa-8-971],[@b13-ppa-8-971],[@b14-ppa-8-971] The respondents were taking first-line injectable (109, 35.4%), infusion (71, 23.1%), and oral (128, 41.6%) DMTs. For comparison, the distribution of DMTs for the fall 2011 survey (n=8,707) shows that 53.2% of responders were taking a first-line injectable DMT, 8.6% were taking an infusion DMT, and 3.2% were taking an oral DMT. None of the factors in [Table 1](#t1-ppa-8-971){ref-type="table"} differed by the current DMT group. Overall, three-quarters of participants had been on their prior DMT for 1 year or more prior to switching. Of those switching to first-line injectables, 69.5% had been on their prior DMT for 1 year or more, while 85.7% of those switching to infusions and 81.3% of those switching to oral DMTs had been on their prior DMT for 1 year or more. Most participants who switched to a first-line injectable DMT (73.3%) had been taking another first-line injectable immediately prior to the switch, as had those who switched to an oral (66.7%) or infusion (90.0%) DMT.

Initiating differences
----------------------

The origin of the discussion to switch was split almost equally between the participant initiating the conversation (49.0%) and the physician suggesting the idea (48.7%); 1.3% selected both choices (n=4). There were no differences in demographic and clinical factors and most recent past DMT; however, a higher proportion of participants initiated the discussion when switching to an oral DMT compared to those switching to a first-line injectable or infusion therapy ([Table 2](#t2-ppa-8-971){ref-type="table"}). The four participants who selected both themselves and their physician as having initiated the discussion had switched to an oral DMT. Of those participants who had initiated the discussion to switch with their physician, 39% reported asking because of adverse effects and 32.9% because of the participant-reported, perceived lack of effectiveness of their past DMT (see the Discussion section and [Figure 1](#f1-ppa-8-971){ref-type="fig"}).

Switching-associated factors
----------------------------

While there may be many factors that motivate participants to switch DMT, the survey aimed to identify the main reason for the change in DMT. Overall, doctor's recommendation (75, 24.5%) was the most frequently reported main reason to switch DMT, followed by perceived lack of efficacy (42, 13.7%). [Table 3](#t3-ppa-8-971){ref-type="table"} shows the variation in the main reasons for switching from the most immediate past DMT stratified by current DMT. The main reasons for switching were similar between the physician-initiated and the participant-initiated switchers, with the exception of the patient-initiated switchers having a lower proportion (11.0% versus 39.2%) of switching primarily because of the doctor's recommendation and a higher proportion (17.1% versus 4.7%) of switching because of a dislike of the infusions or injections ([Table 2](#t2-ppa-8-971){ref-type="table"}). Other reasons considered by over 30% of participants for switching included adverse effects and lack of efficacy.

We also asked about other issues surrounding the decision to switch. Currently, 74% of the participants would not consider switching back to their previous medications or trying something else. Stratified by current DMT group, those on an oral DMT were more likely to prefer staying on their DMT (81.3%) than those on infusion DMT (77.5%) or first-line injectables (63.6%) (*P*=0.005). However, those on an oral DMT were also the most likely to have initiated the discussion to switch DMTs. A large proportion of participants (89%) felt they had adequate information about their new treatment at the time of the switch. Only 14.4% reported using information on the internet as the basis for initiating the discussion. In terms of changing DMT again, those taking a first-line injectable were 2.6 (95% confidence interval \[CI\]: \[1.45, 4.91\]) and 2.1 (95% CI \[1.04, 4.2\]) times more likely to consider switching back than those taking an oral (*P*=0.0014) or infusion (*P*=0.039) DMT, respectively.

Clinical factors
----------------

Respondents' clinical status was investigated using relapse and symptom worsening history from the year prior to the switch. Overall (n=237), 47.3% of switchers reported relapse activity in the year prior; 59.5% reported symptom worsening in 2010; and 76.0% reported having either relapse activity or symptom worsening (ie, disease activity). No differences in having disease activity were found between DMT groups (*P*=0.70). Participants who initiated the switch did not differ from physician-initiated switchers regarding reported disease activity (*P*=0.35). The median (IQR) PDDS score was higher for those with activity (4 \[2--5\]) and those without activity (2 \[1--4\]) (Wilcoxon, *P*=0.005). The main reasons for switching among those with no disease activity were doctor's recommendation (21.1%) and dislike of injections/infusions (17.5%), while the main reasons for switching among those with some activity were doctor's recommendation (27.5%) and adverse effects (15.7%). [Figure 3A and B](#f3-ppa-8-971){ref-type="fig"} compare clinical status for physician-initiated and participant-initiated switches by DMT group. When looking within a current DMT group, participant-initiated switchers currently taking either first-line injectables or oral DMTs had a higher proportion with no relapse activity with a similar proportion reporting no relapse activity in the physician-initiated switchers on first-line injectables (*P*=0.009). The absence of reported symptom worsening did not differ within DMT groups between participant-initiated switchers and physician-initiated switchers (*P*=0.15).

Other areas of interest
-----------------------

Almost 85% of responders ranked the physician managing their MS as the most trusted source of treatment option information. Among those who ranked their doctor as one of their most trusted sources (first, second, or third), there were no statistically significant differences by the current DMT group or by the type of physician managing their MS. After a median of 7--12 months on their current DMT, 38% of responders (13.6% on first-line injectables, 7.5% on an infusion DMT, 16.9% on an oral DMT) were unsure or considered it too early to rate the effectiveness of the new DMT to which they had switched. Among those who did rate the effectiveness, 44.6% of first-line injectable, 45.8% of infusion, and 56.9% of oral DMT users perceived their current DMT to be very or extremely effective (*P*=0.29).

Discussion
==========

We described the patient's perspectives on issues surrounding the decision to switch DMTs. The results reflect the experience of individuals who have had MS for an average of 14 years (range: 1--47 years) with comparable sociodemographic characteristics across the DMT groups. Responders reported taking a substantial role in initiating the discussion of changing their DMT. While patients with MS were clearly involved in discussing changes in DMT, treatment recommendations and medication information provided by treating physicians played an important role in the choice of DMT. Strikingly, the reasons for switching DMT were similar whether the switch was initiated by the participant or the physician.

Little information is available regarding the patient perspectives about switching DMTs, quantifying issues of importance, and potentially identifying appropriate opportunities to initiate conversations regarding alternatives. This makes it necessary for physicians to rely on their own possibly limited experience and clinical guidelines. Consensus papers may provide a summary of what a group feels is reasonable to warrant a switch, but the papers may not encompass all scenarios a physician may encounter nor address patient perspectives. Shared decision-making (SDM) has emerged as a concept that focuses on patient and physician communication in the medical decision-making process and is well suited to practice in MS.[@b15-ppa-8-971],[@b16-ppa-8-971] SDM involves the exchange of information between the physician and patient, where physicians contribute experience and information while the patient communicates their values, risk attitudes, and treatment goals.[@b4-ppa-8-971],[@b15-ppa-8-971],[@b17-ppa-8-971] Heesen et al[@b15-ppa-8-971] found that 80% of MS patients in pilot studies wanted an autonomous role in the decision-making process. Involving and educating the patient in the SDM process improves health outcomes and quality of life in other chronic diseases such as diabetes.[@b18-ppa-8-971] While the desire for a shared role in management is not universal with all MS patients, its importance will likely increase in the management of MS over time as treatment options and evidence for outcomes evolve. This study shows that patients from a sociodemographically diverse population already play an active role in some form of SDM regarding the switching of their treatments.

This study has several limitations. There were nonresponders to the switching survey and responders who did not qualify for this study, and this represents a potential source of bias. However, the nonresponders are comparable to those participants included in the analysis, and those excluded from the study are likely to include those who did not actually switch DMTs. Refinement of the single switching question may be needed to more accurately capture future switchers in the database. Also, there is likely to be recall error in the participants' answers; however, we attempted to minimize this potential bias by including only recent switchers. The physician perspective regarding switching was not captured in this study and would provide additional important information in future studies, especially if it could be obtained for specific patient and physician dyads to compare the perspectives regarding the same treatment decision. This study did not evaluate the impact of switching on outcomes, or whether this differed by reason for switching.

Previous studies have examined clinical outcomes after switching DMTs when breakthrough disease occurs, a paradigm that will continue to change with the increase in treatment options.[@b19-ppa-8-971]--[@b21-ppa-8-971] Patients who switched prior to the availability of oral DMTs may have switched for different reasons than those who switch with other treatment options available (ie, perceived convenience). Longitudinal follow-up of these registry participants will provide valuable information on both their disease trajectory, reasons for switching, satisfaction with the chosen therapy, and effectiveness of their new medication.
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![Response options for specific questions in the NARCOMS Patient's Perspective survey.\
**Notes:** (**A**) Decision (asked of all participants). (**B**) Discussion (asked only of participant-initiated switchers).\
**Abbreviations:** JCV, John Cunningham virus; NARCOMS, North American Research Committee on Multiple Sclerosis; PML, progressive multifocal leukoencephalopathy.](ppa-8-971Fig1){#f1-ppa-8-971}

![Cohort selection diagram.\
**Abbreviations:** IM, intramuscular; SC, subcutaneous.](ppa-8-971Fig2){#f2-ppa-8-971}

![Relapse activity and reported symptom worsening by DMT group and initiating group.\
**Notes:** (**A**) Proportion with no reported relapse activity in the year prior to switch within the current DMT group by initiating group (physician or participant) (*P*=0.009). (**B**) Proportion with no reported symptom worsening in the year prior to switch within the current DMT group by initiating group (physician or participant) (*P*=0.15).](ppa-8-971Fig3){#f3-ppa-8-971}

###### 

Sample characteristics

  Characteristic                        All (n=308)   First-line injectables (n=109)   Infusions (n=71)   Oral therapies (n=128)
  ------------------------------------- ------------- -------------------------------- ------------------ ------------------------
  Female, n (%)                         257 (83.4)    95 (87.2)                        60 (84.5)          102 (79.7)
  Caucasian, n (%)                      267 (97.1)    98 (98.0)                        62 (96.9)          107 (96.4)
  Education level, n (%)                                                                                  
   High school or less                  89 (29.0)     31 (28.4)                        17 (24.3)          41 (32.0)
   Associate's or technical degree      51 (16.6)     21 (19.3)                        11 (15.7)          19 (14.8)
   Bachelor's degree                    89 (29.0)     32 (29.4)                        20 (28.6)          37 (28.9)
   Postgraduate degree                  78 (25.4)     25 (22.9)                        22 (31.4)          31 (24.2)
  Annual income (USD), n (%)                                                                              
   \<\$15,000                           23 (7.6)      9 (8.3)                          3 (4.3)            11 (8.7)
   \$15,000--\$29,999                   41 (13.5)     16 (14.8)                        11 (15.7)          14 (11.1)
   \$30,000--\$49,999                   40 (13.2)     17 (15.7)                        10 (14.3)          13 (10.3)
   \$50,000--\$100,000                  85 (28.0)     33 (30.6)                        18 (25.7)          34 (27.0)
   \>\$100,000                          60 (19.7)     15 (13.9)                        15 (21.4)          30 (23.8)
   Declined to answer                   55 (18.1)     18 (16.7)                        13 (18.6)          24 (19.0)
  Health insurance, n (%)                                                                                 
   Private                              227 (74.4)    77 (72.0)                        53 (74.6)          97 (76.4)
   Public only                          70 (23.0)     27 (25.2)                        15 (21.1)          28 (22.0)
   None                                 8 (2.6)       3 (2.8)                          3 (4.2)            2 (1.6)
  Age (years), mean (SD)                52 (9.7)      52.2 (10.3)                      50.2 (10.9)        52.1 (8.4)
  Disease duration (years), mean (SD)   13.9 (8.6)    13.2 (7.7)                       13.3 (9.8)         14.8 (8.5)
  PDDS score, median (IQR)              4 (2--5)      4 (2--5)                         4 (2--5)           3 (1--5)
  MS type, n (%)                                                                                          
   RRMS                                 218 (70.8)    80 (73.4)                        49 (69.0)          89 (69.5)
   SPMS                                 62 (20.1)     22 (20.2)                        13 (18.3)          27 (21.1)
   Unsure                               25 (8.1)      7 (6.4)                          9 (12.7)           9 (7.0)
   RRMS/SPMS                            3 (1.0)       --                               --                 3 (2.3)
  Provider managing care, n (%)                                                                           
   Neurologist, MS specialist           208 (68.9)    71 (65.7)                        51 (72.9)          86 (69.4)
   Neurologist, non-MS specialist       56 (18.5)     20 (18.5)                        10 (14.3)          26 (21.0)
   Primary health care provider         20 (6.6)      7 (6.5)                          5 (7.1)            8 (6.5)
   Other                                18 (6.0)      10 (9.3)                         4 (5.7)            4 (3.2)

**Abbreviations:** IQR, interquartile range; MS, multiple sclerosis; PDDS, Patient-Determined Disease Steps; RRMS, relapsing-remitting MS; SD, standard deviation; SPMS, secondary-progressive MS; USD, US dollars.

###### 

Comparison of demographic and clinical factors between participant- and physician-initiated switchers

                                        Participant-initiated (n=146)   Physician-initiated (n=148)   *P*-value
  ------------------------------------- ------------------------------- ----------------------------- -----------
  Female, n (%)                         118 (81)                        127 (86)                      0.25
  Caucasian, n (%)                      124 (96)                        130 (98)                      0.45
  Age (years), mean (SD)                51.7 (8.9)                      51.4 (10.5)                   0.79
  Disease duration (years), mean (SD)   13.5 (7.3)                      13.7 (9.4)                    0.81
  PDDS score, n (%)                                                                                   
   0 (normal)                           15 (10)                         15 (10)                       0.19
   1 (mild disability)                  18 (12)                         20 (14)                       
   2 (moderate disability)              18 (12)                         9 (6)                         
   3 (gait disability)                  26 (18)                         21 (14)                       
   4 (early cane)                       30 (21)                         37 (25)                       
   5 (late cane)                        21 (14)                         15 (10)                       
   6 (bilateral support)                13 (9)                          19 (13)                       
   7 (wheelchair/scooter)               5 (3)                           12 (8)                        
  Physician managing MS, n (%)                                                                        
   Neurologist, MS specialist           102 (71)                        100 (68)                      0.06
   Neurologist, non-MS specialist       30 (21)                         24 (16)                       
   Primary care physician               9 (6)                           10 (7)                        
   Other                                3 (2)                           13 (9)                        
  DMT switched to, n (%)                                                                              
   First-line injectable                48 (33)                         56 (38)                       0.03
   Infusion therapy                     27 (18)                         41 (28)                       
   Oral DMT                             71 (49)                         51 (34)                       
  Past DMTs, n (%)                                                                                    
   First-line injectable                106 (75)                        109 (75)                      0.62
   Infusion therapy                     23 (16)                         27 (19)                       
   Oral DMT                             4 (3)                           5 (3)                         
   Other                                8 (6)                           4 (3)                         
  Main reason for switching, n (%)                                                                    
   Doctor's recommendation              16 (11.0)                       58 (39.2)                     0.27
   Side effect profile                  16 (11.0)                       11 (7.4)                      
   Dislike of injections/infusions      25 (17.1)                       7 (4.7)                       
   Efficacy                             20 (13.7)                       19 (12.8)                     
   Safety                               7 (4.8)                         7 (4.7)                       
   Results of JCV antibody test         1 (0.7)                         6 (4.1)                       
   Convenience                          11 (7.5)                        2 (1.4)                       
   Cost                                 1 (0.7)                         1 (0.7)                       
   Insurance coverage                   1 (0.7)                         3 (2.0)                       
   Nothing else available               5 (3.4)                         8 (5.4)                       
   Other                                21 (14.4)                       11 (7.4)                      
   Multiple answered                    21 (14.4)                       14 (9.5)                      
   Not answered                         1 (0.7)                         1 (0.7)                       

**Abbreviations:** JCV, John Cunningham virus; DMT, disease-modifying therapy; MS, multiple sclerosis; PDDS, Patient-Determined Disease Steps; SD, standard deviation.

###### 

Primary reason for switching therapy by current and most recent past therapy

  Current therapy         Most recent past therapy     Doctor's recommendation   Side effect profile   Dislike of injections/infusions   Efficacy   Safety   Results of JCV antibody test   Convenience   Cost   Insurance coverage   Nothing else available   Other   Multiple answered   Not answered
  ----------------------- ---------------------------- ------------------------- --------------------- --------------------------------- ---------- -------- ------------------------------ ------------- ------ -------------------- ------------------------ ------- ------------------- --------------
  First-line injectable   Any past therapy (n=104)\*   26.0                      14.4                  0.0                               6.7        9.6      3.8                            3.8           2.9    2.9                  5.8                      14.4    9.6                 0
  First-line injectable   21                           12                        --                    4                                 7          1        4                              3             3      5                    8                        8       --                  
  Infusions               2                            1                         --                    1                                 2          3        --                             --            --     1                    4                        2       --                  
  Oral therapies          1                            2                         --                    2                                 --         --       --                             --            --     --                   3                        --      --                  
  Other                   3                            --                        --                    --                                1          --       --                             --            --     --                   --                       --      --                  
  Infusions               Any past therapy (n=70)\*    28.6                      1.4                   2.9                               31.4       2.9      2.9                            1.4           0.0    0.0                  1.4                      11.4    12.9                2.9
  First-line injectable   20                           1                         2                     17                                2          2        1                              --            --     1                    7                        8       2                   
  Infusions               --                           --                        --                    2                                 --         --       --                             --            --     --                   1                        --      --                  
  Oral therapies          --                           --                        --                    1                                 --         --       --                             --            --     --                   --                       1       --                  
  Other                   --                           --                        --                    2                                 --         --       --                             --            --     --                   --                       --      --                  
  Oral therapies          Any past therapy (n=123)\*   22.8                      8.9                   25.2                              9.8        2.4      2.4                            6.5           0.0    0.8                  3.3                      4.9     13.0                0.0
  First-line injectable   20                           7                         26                    9                                 1          --       4                              --            1      1                    2                        11      --                  
  Infusions               6                            4                         5                     1                                 2          3        4                              --            --     3                    3                        4       --                  
  Other                   2                            --                        --                    2                                 --         --       --                             --            --     --                   1                        1       --                  

**Note:** Data shown as number of subjects (n) except for \*percentage of subjects.

**Abbreviation:** JCV, John Cunningham virus.
